Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

BACKGROUND: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF discontinuation. Alternative dosing strategies may help patients continue their therapy. METHODS: In this multicenter, double-bl...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Chron Obstruct Pulmon Dis
Main Authors: Watz, Henrik, Bagul, Nitin, Rabe, Klaus F, Rennard, Stephen, Alagappan, Vijay KT, Román, Jonas, Facius, Axel, Calverley, Peter MA
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846760/
https://ncbi.nlm.nih.gov/pubmed/29563781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S154012
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares